White Paper

Flexible Platform Solutions Overcome Vaccine Production Challenges

Source: Pall
Packaging vaccine syringe world

Vaccines have been used since Edward Jenner first experimented with smallpox in the 1790s and have evolved significantly in modern times. Today, vaccines have a diversity of antigens and targets, and with advances in drug manufacturing there is a huge variety of development and administration formats.

The team from Pall Biotech explores the challenges of vaccine development and how they can be overcome by applying a quality by design (QbD) platform approach from early process development phases forward. The impact of the COVID-19 pandemic on vaccine production is evaluated, with insight on how flexible, integrated, closed-system processing is advancing the future of safe and efficacious vaccine production.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: